Evidence map›Paper›PMID 26464630›Full record

Trial reportInternational journal of clinical and experimental pathology2015

Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.

Nannan Pang, Xianlin Duan, Ming Jiang, Jianhua Qu, Hailong Yuan, Jianli Xu, Haizhou Cao, Gang Chen

Abstract readClinical Trial
In one paragraph

Trial report in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The level of Tim-3+CD8+ T cells can serve as a potential marker for evaluating the severity of acute graft-versus-host disease after haplo-PBSCT.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023
    Article
  5. Article
  6. [Research advances in immune tolerance of allogeneic cell transplantation in preterm infants].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nannan PangInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Xianlin DuanInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Ming JiangInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Jianhua QuInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Hailong YuanInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Jianli XuInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Haizhou CaoInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.
Gang ChenInstitute of Hematology, Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University Xinjiang Uygur Autonomous Region Research, Urumqi 830011, Xinjiang Uygur Autonomous Region, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Related HLA-haploidentical HSCT has been applied more and more recently, but the reconstitution of T lymphocyte subsets and its clinical significance in patients received related HLA-haploidentical non T-cell depleted in vitro high-dose peripheral blood hematopoietic SCT (RHNT-PSCT) are incompletely defined. In the present study of our RHNT-PSCT, we found that in non-aGVHD group, CD3(+) T lymphocyte recovered to normal levels gradually between 60 and 90 days, and the recovery of CD4(+) T lymphocyte was retarded significantly, CD4(+)/CD8(+) ratio was apparently inverted. Whereas, the ratio of CD4(+) CD25(+) Foxp3(+) Treg cells was significantly lower in aGVHD group than in healthy control group and non-aGVHD group, and also in grade III-IV aGVHD patients than in grade I-II aGVHD patients. Meanwhile, we observed the level of interleukin-10 (IL-10) gradually increased in serum of patients without aGVHD, but decreased in III-IV aGVHD patients significantly. Spearman correlation analysis showed that serum IL-10 level was negatively correlated with the grade of aGVHD. These results suggest that the reconstitution of peripheral blood T lymphocyte subsets is good, and dynamic detection of Treg cells and serum IL-10 level might predict aGVHD in the early stage after our RHNT-PSCT.

Indexed as

AdolescentAdultChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleFlow CytometryGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHLA AntigensHumansMaleMiddle AgedT-Lymphocyte SubsetsYoung AdultHLA Antigensacute GVHDAllo-HSCTHLA-mismatchedlymphocyte subsetsregulatory T-cell

Identifiers

PMID26464630
PMCPMC4583862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.